About this Journal Submit a Manuscript Table of Contents
Journal of Allergy
Volume 2011 (2011), Article ID 279425, 5 pages
http://dx.doi.org/10.1155/2011/279425
Review Article

Atopic Dermatitis and the Atopic March: What Is New?

1Division of Dermatology, Department of Internal Medicine, Geriatrics and Nephrology, University of Bologna, Via Massarenti 1, 40138 Bologna, Italy
2Department of Pediatrics, University of Bologna, Via Massarenti 9, 40138 Bologna, Italy

Received 8 April 2011; Accepted 14 June 2011

Academic Editor: Fabienne Rancé

Copyright © 2011 Annalisa Patrizi et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. G. Ricci, A. Patrizi, A. Giannetti, A. Dondi, B. Bendandi, and M. Masi, “Does improvement management of atopic dermatitis influence the appearance of respiratory allergic diseases? A follow-up study,” Clinical and Molecular Allergy, vol. 8, article no. 8, 2010. View at Publisher · View at Google Scholar · View at PubMed
  2. J. M. Spergel and A. S. Paller, “Atopic dermatitis and the atopic march,” Journal of Allergy and Clinical Immunology, vol. 112, no. 6, pp. S118–S127, 2003. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  3. J. M. Spergel, “From atopic dermatitis to asthma: the atopic march,” Annals of Allergy, Asthma and Immunology, vol. 105, no. 2, pp. 99–106, 2010. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  4. E. Besnier, “Premiere note et observations preliminaires pour servir d'introduction a l'etude diathesques,” Annales de Dermatologie et de Syphiligraphie, vol. 4, p. 634, 1892.
  5. J. M. Hanifin and G. Rajka, “Diagnostic features of Atopic Dermatitis,” Acta Dermato-Venereologica, vol. 92, supplement, pp. 44–47, 1980.
  6. S. G. O. Johansson, T. Bieber, R. Dahl et al., “Revised nomenclature for allergy for global use: report of the Nomenclature Review Committee of the World Allergy Organization, October 2003,” Journal of Allergy and Clinical Immunology, vol. 113, no. 5, pp. 832–836, 2004. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  7. A. Sandilands, C. Sutherland, A. D. Irvine, and W. H. I. McLean, “Filaggrin in the frontline: role in skin barrier function and disease,” Journal of Cell Science, vol. 122, no. 9, pp. 1285–1294, 2009. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  8. F. J. D. Smith, A. D. Irvine, A. Terron-Kwiatkowski et al., “Loss-of-function mutations in the gene encoding filaggrin cause ichthyosis vulgaris,” Nature Genetics, vol. 38, no. 3, pp. 337–342, 2006. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  9. H. Baurecht, A. D. Irvine, N. Novak et al., “Toward a major risk factor for atopic eczema: meta-analysis of filaggrin polymorphism data,” Journal of Allergy and Clinical Immunology, vol. 120, no. 6, pp. 1406–1412, 2007. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  10. S. Weidinger, M. O'Sullivan, T. Illig et al., “Filaggrin mutations, atopic eczema, hay fever, and asthma in children,” Journal of Allergy and Clinical Immunology, vol. 121, no. 5, pp. 1203–1209.e1, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  11. C. N. A. Palmer, A. D. Irvine, A. Terron-Kwiatkowski et al., “Common loss-of-function variants of the epidermal barrier protein filaggrin are a major predisposing factor for atopic dermatitis,” Nature Genetics, vol. 38, no. 4, pp. 441–446, 2006. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  12. J. Henderson, K. Northstone, S. P. Lee et al., “The burden of disease associated with filaggrin mutations: a population-based, longitudinal birth cohort study,” Journal of Allergy and Clinical Immunology, vol. 121, no. 4, pp. 872–877.e9, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  13. C. N. A. Palmer, T. Ismail, S. P. Lee et al., “Filaggrin null mutations are associated with increased asthma severity in children and young adults,” Journal of Allergy and Clinical Immunology, vol. 120, no. 1, pp. 64–68, 2007. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  14. I. Marenholz, R. Nickel, F. Rüschendorf et al., “Filaggrin loss-of-function mutations predispose to phenotypes involved in the atopic march,” Journal of Allergy and Clinical Immunology, vol. 118, no. 4, pp. 866–871, 2006. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  15. J. Bousquet, N. Khaltaev, A. A. Cruz et al., “Allergic rhinitis and its impact on asthma (ARIA) 2008 update (in collaboration with the World Health Organization, GA(2)LEN and AllerGen),” Allergy, vol. 63, no. 86, pp. 8–160, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  16. J. D. Boot, P. Panzner, and Z. Diamant, “A critical appraisal of methods used in early clinical development of novel drugs for the treatment of asthma,” Pulmonary Pharmacology and Therapeutics, vol. 20, no. 3, pp. 201–219, 2007. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  17. A. H. Liu, F. D. Martinez, and L. M. Taussig, “Natural history of allergic diseases and asthma,” in Pediatric Allergy: Principles and Practice, D. Y. M. Leung, H. A. Sampson, R. S. Geha, and S. J. Szefler, Eds., pp. 10–22, Elsevier, Philadelphia, Pa, USA, 2003.
  18. M. Kulig, R. Bergmann, U. Klettke, V. Wahn, U. Tacke, and U. Wahn, “Natural course of sensitization to food and inhalant allergens during the first 6 years of life,” Journal of Allergy and Clinical Immunology, vol. 103, no. 6, pp. 1173–1179, 1999. View at Publisher · View at Google Scholar · View at Scopus
  19. G. Ricci, A. Patrizi, E. Baldi, G. Menna, M. Tabanelli, and M. Masi, “Long-term follow-up of atopic dermatitis: retrospective analysis of related risk factors and association with concomitant allergic diseases,” Journal of the American Academy of Dermatology, vol. 55, no. 5, pp. 765–771, 2006. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  20. Y. Ohshima, A. Yamada, M. Hiraoka et al., “Early sensitization to house dust mite is a major risk factor for subsequent development of bronchial asthma in Japanese infants with atopic dermatitis: Results of a 4-year followup study,” Annals of Allergy, Asthma and Immunology, vol. 89, no. 3, pp. 265–270, 2002. View at Scopus
  21. A. E. van der Hulst, H. Klip, and P. L. P. Brand, “Risk of developing asthma in young children with atopic eczema: a systematic review,” Journal of Allergy and Clinical Immunology, vol. 120, no. 3, pp. 565–569, 2007. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  22. J. M. Hanifin and W. C. Lobitz Jr., “Newer concepts of atopic dermatitis,” Archives of Dermatology, vol. 113, no. 5, pp. 663–670, 1977. View at Publisher · View at Google Scholar · View at Scopus
  23. H. Gu, X. S. Chen, K. Chen et al., “Evaluation of diagnostic criteria for atopic dermatitis: validity of the criteria of Williams et al. in a hospital-based setting,” British Journal of Dermatology, vol. 145, no. 3, pp. 428–433, 2001. View at Publisher · View at Google Scholar · View at Scopus
  24. J. F. Stalder, A. Taieb, D. J. Atherton et al., “Severity scoring of atopic dermatitis: the SCORAD index. Consensus report of the European Task Force on Atopic Dermatitis,” Dermatology, vol. 186, no. 1, pp. 23–31, 1993. View at Scopus
  25. A. P. Oranje, E. J. Glazenburg, A. Wolkerstorfer, and F. B. De Waard-Van Der Spek, “Practical issues on interpretation of scoring atopic dermatitis: the SCORAD index, objective SCORAD and the three-item severity score,” British Journal of Dermatology, vol. 157, no. 4, pp. 645–648, 2007. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  26. A. P. Oranje, “Practical issues on interpretation of scoring atopic dermatitis: SCORAD index, objective SCORAD, patient-oriented SCORAD and three-item severity score,” Current Problems in Dermatology, vol. 41, pp. 149–155, 2011. View at Publisher · View at Google Scholar · View at PubMed
  27. J.-F. Stalder, S. Barbarot, A. Wollenberg et al., “Patient oriented SCORAD (PO-SCORAD): a new self assesment scale in atopic dermatitis, validated in Europe,” Allergy, vol. 66, no. 8, pp. 1114–1121, 2011. View at Publisher · View at Google Scholar · View at PubMed
  28. J. M. Hanifin, M. Thurston, M. Omoto, R. Cherill, S. J. Tofte, and M. Graeber, “The eczema area and severity index (EASI): assessment of reliability in atopic dermatitis,” Experimental Dermatology, vol. 10, no. 1, pp. 11–18, 2001. View at Publisher · View at Google Scholar
  29. C. R. Charman, A. J. Venn, and H. C. Williams, “The patient-oriented eczema measure: development and initial validation of a new tool for measuring atopic eczema severity from the patients' perspective,” Archives of Dermatology, vol. 140, no. 12, pp. 1513–1519, 2004. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  30. L. F. Eichenfield, A. W. Lucky, M. Boguniewicz et al., “Safety and efficacy of pimecrolimus (ASM 981) cream 1% in the treatment of mild and moderate atopic dermatitis in children and adolescents,” Journal of the American Academy of Dermatology, vol. 46, no. 4, pp. 495–504, 2002. View at Publisher · View at Google Scholar · View at Scopus
  31. H. Gollnick, R. Kaufmann, D. Stough et al., “Pimecrolimus cream 1% in the long-term management of adult atopic dermatitis: prevention of flare progression. A randomized controlled trial,” British Journal of Dermatology, vol. 158, no. 5, pp. 1083–1093, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  32. J. Schmitt, S. Langan, and H. C. Williams, “What are the best outcome measurements for atopic eczema? A systematic review,” Journal of Allergy and Clinical Immunology, vol. 120, no. 6, pp. 1389–1398, 2007. View at Publisher · View at Google Scholar · View at PubMed
  33. L. F. Eichenfield, J. M. Hanifin, T. A. Luger, S. R. Stevens, and H. B. Pride, “Consensus conference on pediatric atopic dermatitis,” Journal of the American Academy of Dermatology, vol. 49, no. 6, pp. 1088–1095, 2003. View at Publisher · View at Google Scholar · View at Scopus
  34. C. Ellis, T. Luger, D. Abeck et al., “International Consensus Conference on Atopic Dermatitis II (ICCAD II): clinical update and current treatment strategies,” The British Journal of Dermatology, vol. 148, supplement 63, pp. 3–10, 2003.
  35. J. M. Hanifin, K. D. Cooper, V. C. Ho et al., “Guidelines of care for atopic dermatitis,” Journal of the American Academy of Dermatology, vol. 50, no. 3, pp. 391–404, 2004. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  36. C. A. Akdis, M. Akdis, T. Bieber et al., “Diagnosis and treatment of atopic dermatitis in children and adults: European Academy of Allergology and Clinical Immunology/American Academy of Allergy, Asthma and Immunology/PRACTALL consensus report,” Allergy, vol. 61, no. 8, pp. 969–987, 2006. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  37. T. Bieber, M. Cork, C. Ellis et al., “Consensus statement on the safety profile of topical calcineurin inhibitors,” Dermatology, vol. 211, no. 2, pp. 77–78, 2005. View at Publisher · View at Google Scholar · View at PubMed
  38. L. Fonacier, E. N. Charlesworth, J. M. Spergel, and D. Y. M. Leung, “The black box warning for topical calcineurin inhibitors: looking outside the box,” Annals of Allergy, Asthma and Immunology, vol. 97, no. 1, pp. 117–120, 2006. View at Scopus
  39. J. M. Spergel and D. Y. M. Leung, “Safety of topical calcineurin inhibitors in atopic dermatitis: evaluation of the evidence,” Current Allergy and Asthma Reports, vol. 6, no. 4, pp. 270–274, 2006. View at Publisher · View at Google Scholar · View at Scopus
  40. A. B. Fleischer Jr., “Black box warning for topical calcineurin inhibitors and the death of common sense,” Dermatology Online Journal, vol. 12, no. 6, article no. 2, 2006.
  41. G. Ricci, A. Dondi, and A. Patrizi, “Role of topical calcineurin inhibitors on atopic dermatitis of children,” Current Medicinal Chemistry, vol. 14, no. 14, pp. 1579–1591, 2007. View at Publisher · View at Google Scholar · View at Scopus
  42. J. Schmitt, L. Von Kobyletzki, Å. Svensson, and C. Apfelbacher, “Efficacy and tolerability of proactive treatment with topical corticosteroids and calcineurin inhibitors for atopic eczema: systematic review and meta-analysis of randomized controlled trials,” British Journal of Dermatology, vol. 164, no. 2, pp. 415–428, 2011. View at Publisher · View at Google Scholar · View at PubMed
  43. R. S. Kirsner, M. P. Heffernan, and R. Antaya, “Safety and efficacy of tacrolimus ointment versus pimecrolimus cream in the treatment of patients with atopic dermatitis previously treated with corticosteroids,” Acta Dermato-Venereologica, vol. 90, no. 1, pp. 58–64, 2010. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  44. G. Ricci, B. Bendandi, F. Bellini, A. Patrizi, and M. Masi, “Atopic dermatitis: quality of life of young Italian children and their families and correlation with severity score,” Pediatric Allergy and Immunology, vol. 18, no. 3, pp. 245–249, 2007. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  45. V. Lawson, M. S. Lewis-Jones, A. Y. Finlay, P. Reid, and R. G. Owens, “The family impact of childhood atopic dermatitis: the Dermatitis Family Impact questionnaire,” British Journal of Dermatology, vol. 138, no. 1, pp. 107–113, 1998. View at Publisher · View at Google Scholar · View at Scopus
  46. U. Pauli-Pott, A. Darui, and D. Beckmann, “Infants with atopic dermatitis: maternal hopelessness, child-rearing attitudes and perceived infant temperament,” Psychotherapy and Psychosomatics, vol. 68, no. 1, pp. 39–45, 1999. View at Publisher · View at Google Scholar
  47. S. Illi, E. Von Mutius, S. Lau et al., “The natural course of atopic dermatitis from birth to age 7 years and the association with asthma,” Journal of Allergy and Clinical Immunology, vol. 113, no. 5, pp. 925–931, 2004. View at Publisher · View at Google Scholar · View at PubMed